Treatment of endometrial cancer in these populations is a challenge as surgery is indicated in the vast majority of cases, and there are no validated screening tools to assess a patient's fitness for endometrial cancer surgery. Patients with endometrial cancer not uncommonly require adjuvant therapy ...
In the United States,endometrial canceris the most common cancer of the female reproductive system. The upside is that most women are diagnosed when the cancer is at an early stage. This means that for many women, endometrial cancer can be cured with surgery alone. While surgery is the first...
Like tumors of the breast and prostate,endometrial canceris regulated by hormones. Unlike therapies for breast andprostate cancer, where drugs are given to block hormone signaling, in therapy for endometrialcancerprogesterone is given to stimulate itshormone receptor. Although it has been used for sev...
Although most patients with endometrial cancer are cured with hysterectomy alone, a subset of patients with relatively high-risk disease may benefit from effective adjuvant treatments. Investigators are still attempting to define the indications for and risks and benefits of additional interventions, includ...
EP: 8.Treatment for Recurrent Endometrial Cancer: Chemotherapy or Lenvatinib + Pembrolizumab EP: 9.Endometrial Cancer: Managing Toxicities in Lenvatinib and Pembrolizumab EP: 10.Revolutionizing Frontline Therapy for Endometrial Cancer: Checkpoint Inhibitors and MMR Status EP: 11.Expanding Horizons in Endome...
Treatment for Endometrial Cancer Traditional Anti-cancer Technology Surgical Resection: Big Trauma, high risk, easy to have complications, not suitable for advanced endometrial cancer patient. For some of the endometrial cancer patients, the operation may include removing the uterus, fallopian tubes,...
GSK's Jemperli (dostarlimab) has secured the first-line treatment indication for endometrial cancer ahead of MSD's Keytruda (pembrolizumab), becoming the first immunotherapy in Korea to be approved for both first- and second-line treatment.GSK Korea said
In this issue of ONCOLOGY, Diavolitsis et al have provided an excellent overview of the literature and state of our understanding of the role of adjuvant therapy in the treatment of endometrial cancer. Their analysis brings some order to the confusing array of empirical evidence, traditional belief...
Although the prognosis for women with endometrial cancer confined to the uterus is relatively good, with a 5-year survival of approximately 90%, women with advanced or recurrent disease have a much poorer outcome. Systemic hormonal therapy with progestins improves survival in progesterone-receptor-pos...
by Yale Cancer Center/Smilow Cancer Hospital Credit: Pixabay/CC0 Public Domain The latest trial of a new antibody drug that delivers potent chemotherapy directly to cancer cells for patients with advanced or recurrent endometrial cancer moves ahead to be studied further in a Phase III trial. ...